HUTCHMED Highlights Clinical Data on Fruquintinib, Surufatinib, and Savolitinib at Upcoming Conferences
Key Insights
HUTCHMED will present Phase II trial results of osimertinib plus savolitinib as first-line treatment for EGFRm (search), MET-aberrant advanced NSCLC (search), showing a significantly higher objective response rate compared to osimertinib alone.
Subgroup analyses from the FRESCO-2 trial will be presented, demonstrating the efficacy and safety of fruquintinib in refractory metastatic colorectal cancer (search) patients with and without liver metastasis, and by age.
Data on surufatinib, both as a monotherapy and in combination with other treatments, will be presented for advanced hepatocellular carcinoma (search), neuroendocrine tumors, and soft tissue sarcoma (search).
HUTCHMED is set to present new and updated clinical data on several of its internally discovered compounds at the World Conference on Lung Cancer (WCLC24) and the European Society for Medical Oncology (ESMO) Congress 2024. The presentations will cover a range of studies involving fruquintinib, surufatinib, and savolitinib across various cancer types.
Osimertinib and Savolitinib Combination in NSCLC
At WCLC24, HUTCHMED will share results from the FLOWERS study, a Phase II clinical trial evaluating the combination of osimertinib with or without savolitinib as a first-line treatment for EGFR-mutated, MET-aberrant advanced non-small cell lung cancer (NSCLC (search)). The data, as of May 28, 2024, with a median follow-up of 8.2 months, indicates that patients treated with the combination therapy (n=21) experienced deeper and more durable responses compared to those receiving osimertinib monotherapy (n=23). The confirmed objective response rate (ORR) was 90.5% in the combination arm versus 60.9% in the monotherapy arm. The disease control rate (DCR) was 95.2% and 87%, respectively. Progression-free survival (PFS) data also showed a positive trend favoring the combination, with median PFS of 19.6 months compared to 9.3 months in the osimertinib arm. These results suggest a potential benefit for combining savolitinib with osimertinib in this patient population. The safety profiles were as expected, tolerable, and manageable.
Fruquintinib Studies in Colorectal and Gastric Cancers
ESMO Congress 2024 will feature further analysis of fruquintinib's FRESCO-2 study in metastatic colorectal cancer (search) and the FRUTIGA study in gastric cancer (search). Subgroup analyses from the FRESCO-2 trial will explore the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer, specifically focusing on those with and without liver metastasis, as well as analyses based on patient age. Additionally, data from the FRUTIGA study will be presented, examining the efficacy of fruquintinib plus paclitaxel in patients with prior immunotherapy and the impact of subsequent anti-tumor therapies. An analysis of fruquintinib-induced hypertension and its correlation with clinical outcomes from the FRUTIGA study will also be presented.
Additional Fruquintinib and Surufatinib Studies
Several investigator-initiated studies involving fruquintinib and surufatinib will also be presented at ESMO 2024. These include studies on fruquintinib in combination with toripalimab and short-course radiotherapy for locally advanced rectal cancer (search), fruquintinib combined with sintilimab and chemotherapy for advanced non-squamous NSCLC (search), and fruquintinib combined with nab-paclitaxel and gemcitabine as a first-line treatment for pancreatic ductal adenocarcinoma (search) with liver metastases. Surufatinib studies include its use in combination with anti-PD-1/PD-L1 antibodies for advanced hepatocellular carcinoma (search) and in combination with gemcitabine for soft tissue sarcoma (search).
These presentations promise to provide valuable insights into the potential of HUTCHMED's compounds in addressing unmet needs across a spectrum of cancer types.